Department of Hematology/Hematology Research Laboratory, West China Hospital, Sichuan University, #37 Guo Xue Xiang Street, Chengdu, 610041, China.
Department of Hematology, Affiliated Hospital of Southwest Medical University, Luzhou, China.
Sci Rep. 2021 Jun 7;11(1):11896. doi: 10.1038/s41598-021-91433-7.
Mantle cell lymphoma (MCL) is a relatively rare subtype of non-Hodgkin's lymphoma. To identify molecular biomarkers in MCL, we performed immunohistochemistry tissue arrays using biopsies from 64 MCL patients diagnosed in West China Hospital from 2012 to 2016. TP53 mutation status in those patients was also examined by sequencing. The sequencing results showed TP53 mutations were highly heterogeneous in MCL. We identified four novel TP53 mutations in MCL: P151R, G199R, V218E, and G325R. The MCL patients with TP53 mutations had inferior progression-free survival (PFS, p = 0.002) and overall survival (OS, p = 0.011). Tissue array results showed the expression of p53, Sox11, or Pax5 alone did not correlate with the patient PFS and OS. However, the MCL patients with triple-positive expression of p53/Sox11/Pax5 had inferior PFS (p = 0.008) and OS (p = 0.002). Such risk stratification was independent to the mantle cell lymphoma international prognostic index (MIPI), Ki-67 value, and TP53 mutation status of the patients. The triple-positive patients might represent a subtype of high-risk MCL. Our findings might indicate a novel way to stratify MCL and predict patients' prognosis.
套细胞淋巴瘤（MCL）是一种相对罕见的非霍奇金淋巴瘤亚型。为了鉴定 MCL 中的分子生物标志物，我们使用了 2012 年至 2016 年在华西医院诊断的 64 例 MCL 患者的活检组织进行了免疫组化组织微阵列分析。还通过测序检查了这些患者的 TP53 突变状态。测序结果表明，MCL 中的 TP53 突变高度异质性。我们在 MCL 中鉴定了四个新的 TP53 突变：P151R、G199R、V218E 和 G325R。具有 TP53 突变的 MCL 患者无进展生存期（PFS，p=0.002）和总生存期（OS，p=0.011）较差。组织微阵列结果表明，p53、Sox11 或 Pax5 的单独表达与患者的 PFS 和 OS 无关。然而，p53/Sox11/Pax5 三重阳性表达的 MCL 患者 PFS（p=0.008）和 OS（p=0.002）较差。这种危险分层独立于套细胞淋巴瘤国际预后指数（MIPI）、Ki-67 值和患者的 TP53 突变状态。三重阳性患者可能代表一种高危 MCL 亚型。我们的研究结果可能表明了一种新的分层 MCL 和预测患者预后的方法。
